The National Comprehensive Cancer Network (NCCN) has updated their guidelines for central nervous system cancers to include new systemic therapies for the treatment of brain metastases.
The most recent guidelines address current research in optimal treatment options for a variety of central nervous system cancers, including glioblastoma, oligodendroglioma, and adult intracranial and spinal ependymoma. However, the most substantial additions to the guideline involves systemic therapies for the treatment of brain metastases.
The following recommendations are now included in this section of the guideline:
- Ipilimumab plus nivolumab for metastatic melanoma
- Pembrolizumab for metastatic melanoma or non-small cell lung cancer
- Erlotinib, afatinib, and gefitinib for EGFR-sensitive mutation-positive non-small cell lung cancer
- Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
- Crizotinib for ALK rearrangement-positive or ROS1 rearrangement-positive non-small cell lung cancer
- Ceritinib plus alectinib for ALK rearrangement-positive non-small cell lung cancer
These additions to the guideline are based on the latest evidenced-based research on brain metastasis resulting from melanoma or non-small cell lung cancer.—Zachary Bessette